Abstract 370P
Background
LYMPHA is a relatively new surgical technique that dramatically reduces the incidence of lymphedema following axillary node clearance in breast cancer patients. The technique identifies dominant lymph vessels draining the arm with the aid of dye and, following clearance of the axillary nodes, anastomosing lymphatic vessels to a branch of the axillary vein to enable free drainage of lymphatic fluid. Not currently widely available to breast cancer patients in the UK, this simple surgical procedure carried out at the time of axillary node clearance has been shown to reduce the incidence of lymphedema from 25% to 4%. We report on the establishment of a LYMPHA service at a major London Plastics Centre and first 2 years of its outcomes.
Methods
Suitable patients were referred to plastics by the breast surgery team and seen preoperatively to discuss LYMPHA. Upon agreeing to the procedure, pre-operative measurements of arm volume and arm bioimpedance were completed as well as screening questionnaires on symptoms of lymphedema. Subsequent to the procedure the two measurements and the questionnaires were repeated at 1, 3, 6, 12 and 24 month intervals.
Results
Of 16 patients that have undergone the LYMPHA procedure 0 have experienced signs or symptoms of lymphedema to date. One patient suffered temporary swelling of the arm 1-month post-op which subsequently resolved. No patients have suffered any complications relating to LYMPHA. 1 patient withdrew due to metastatic disease recurrence. The patients enrolled have been followed up for between 3-23 months with a current mean follow up time of 12.61 months.
Conclusions
Our findings thus far support current evidence that LYMPHA surgery is both safe and effective in reducing the incidence of lymphedema. This pilot study is currently being developed into an RCT which will add to the evidence base of this relatively niche area of plastic surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
358P - Major adverse cardiovascular event outcomes of adjuvant taxane + anthracycline versus taxane-based chemotherapy in older adults with triple-negative breast cancer: A SEER-Medicare study
Presenter: Savannah Roy
Session: Poster session 03